NasdaqCM - Delayed Quote USD
Oncternal Therapeutics, Inc. (ONCT)
At close: 4:00 PM EDT
After hours: 4:28 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Expense
37,668.0000
41,714.0000
44,947.0000
31,366.0000
17,542.0000
--
Operating Income
-37,668.0000
-41,714.0000
-44,947.0000
-31,366.0000
-17,542.0000
--
Net Non Operating Interest Income Expense
1,695.0000
2,235.0000
777.0000
33.0000
16.0000
--
Other Income Expense
--
--
--
--
301.0000
-19,356.0000
Pretax Income
-35,973.0000
-39,479.0000
-44,170.0000
-31,333.0000
-17,225.0000
--
Net Income Common Stockholders
-35,973.0000
-39,479.0000
-44,170.0000
-31,333.0000
-17,225.0000
--
Diluted NI Available to Com Stockholders
-35,973.0000
-39,479.0000
-44,170.0000
-31,333.0000
-17,225.0000
--
Basic EPS
-12.18
-13.43
-16.80
-12.80
-17.00
--
Diluted EPS
-12.18
-13.43
-16.80
-12.80
-17.00
--
Basic Average Shares
2,954.5000
2,940.0000
2,629.7000
2,466.0500
1,015.2500
--
Diluted Average Shares
2,954.5000
2,940.0000
2,629.7000
2,466.0500
1,015.2500
--
Total Operating Income as Reported
-37,668.0000
-41,714.0000
-44,947.0000
-31,366.0000
-17,542.0000
--
Total Expenses
37,668.0000
41,714.0000
44,947.0000
31,366.0000
17,542.0000
--
Net Income from Continuing & Discontinued Operation
-35,973.0000
-39,479.0000
-44,170.0000
-31,333.0000
-17,225.0000
--
Normalized Income
-35,973.0000
-39,479.0000
-44,170.0000
-31,333.0000
-17,225.0000
--
Interest Income
1,695.0000
2,235.0000
777.0000
33.0000
16.0000
--
Net Interest Income
1,695.0000
2,235.0000
777.0000
33.0000
16.0000
--
EBIT
-37,668.0000
-41,714.0000
-44,947.0000
-31,366.0000
-17,542.0000
--
EBITDA
-37,668.0000
-41,714.0000
-44,947.0000
-31,366.0000
-17,542.0000
--
Net Income from Continuing Operation Net Minority Interest
-35,973.0000
-39,479.0000
-44,170.0000
-31,333.0000
-17,225.0000
--
Total Unusual Items Excluding Goodwill
--
--
--
--
--
-19,356.0000
Total Unusual Items
--
--
--
--
--
-19,356.0000
Normalized EBITDA
-37,668.0000
-41,714.0000
-44,947.0000
-31,366.0000
-17,542.0000
--
12/31/2019 - 2/3/2004
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
INDP Indaptus Therapeutics, Inc.
1.4300
+11.72%
ESLA Estrella Immunopharma, Inc.
0.8600
+8.18%
MEIP MEI Pharma, Inc.
2.7700
+2.21%
SLRX Salarius Pharmaceuticals, Inc.
1.7100
+12.50%
IMRN Immuron Limited
2.0100
+1.01%
KZR Kezar Life Sciences, Inc.
0.8947
+2.84%
DWTX Dogwood Therapeutics, Inc.
4.4300
+21.04%
LPTX Leap Therapeutics, Inc.
2.4000
+4.80%
SPRB Spruce Biosciences, Inc.
0.5191
+11.11%
ATNF 180 Life Sciences Corp.
6.47
+325.66%